2013
Investigation of the Interactions between Methadone and Elvitegravir-Cobicistat in Subjects Receiving Chronic Methadone Maintenance
Bruce RD, Winkle P, Custodio JM, Wei X, Rhee MS, Kearney BP, Ramanathan S, Friedland GH. Investigation of the Interactions between Methadone and Elvitegravir-Cobicistat in Subjects Receiving Chronic Methadone Maintenance. Antimicrobial Agents And Chemotherapy 2013, 57: 6154-6157. PMID: 24080665, PMCID: PMC3837895, DOI: 10.1128/aac.01229-13.Peer-Reviewed Original ResearchConceptsEVG/COBIBaseline valuesEffect of elvitegravirOpioid-dependence therapiesHIV-seronegative subjectsConcentration-time curveChronic methadone maintenanceDependence therapyOpioid withdrawalMethadone pharmacokineticsDosing periodMethadone maintenanceHistorical controlsPharmacodynamic studiesPharmacokinetic parametersMethadoneCobicistatElvitegravirMean areaAUCtauPharmacodynamicsCmaxSubjectsCOBISteady-state evaluationThe Pharmacokinetic and Pharmacodynamic Interactions Between Buprenorphine/Naloxone and Elvitegravir/Cobicistat in Subjects Receiving Chronic Buprenorphine/Naloxone Treatment
Bruce RD, Winkle P, Custodio JM, Wei LX, Rhee MS, Kearney BP, Ramanathan S, Friedland GH. The Pharmacokinetic and Pharmacodynamic Interactions Between Buprenorphine/Naloxone and Elvitegravir/Cobicistat in Subjects Receiving Chronic Buprenorphine/Naloxone Treatment. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2013, 63: 480-484. PMID: 23599011, DOI: 10.1097/qai.0b013e3182961d31.Peer-Reviewed Original ResearchConceptsEVG/COBIBuprenorphine/naloxoneBaseline valuesBuprenorphine/naloxone treatmentEffect of elvitegravirElvitegravir/cobicistatOpioid-dependence therapiesHIV-seronegative subjectsNorbuprenorphine levelsOpioid pharmacodynamicsOpioid withdrawalNaloxone treatmentPharmacodynamic interactionsBuprenorphine/Historical controlsPharmacodynamic studiesAUCtauCobicistatNaloxoneCmaxElvitegravirTherapySubjectsCOBISteady-state evaluationPharmacokinetic Interactions between Buprenorphine/Naloxone and Raltegravir in Subjects Receiving Chronic Buprenorphine/Naloxone Treatment
Bruce R, Moody DE, Chodkowski D, Andrews L, Fang WB, Morrison J, Parsons TL, Friedland GH. Pharmacokinetic Interactions between Buprenorphine/Naloxone and Raltegravir in Subjects Receiving Chronic Buprenorphine/Naloxone Treatment. The American Journal Of Drug And Alcohol Abuse 2013, 39: 80-85. PMID: 23421567, DOI: 10.3109/00952990.2013.764885.Peer-Reviewed Original ResearchConceptsBuprenorphine/naloxoneHuman immuno-deficiency virusBuprenorphine/Buprenorphine/naloxone treatmentAddition of raltegravirOpioid-dependence therapiesHIV-seronegative subjectsEffect of raltegravirOpioid withdrawalNaloxone treatmentPharmacokinetic interactionsNaloxone concentrationsHistorical controlsPharmacodynamic parametersPharmacodynamic studiesBaseline valuesRaltegravirNaloxoneBuprenorphineSignificant differencesTherapySubjectsPrimary metabolitesSteady-state evaluationPatients
2011
Tipranavir/Ritonavir Induction of Buprenorphine Glucuronide Metabolism in HIV-Negative Subjects Chronically Receiving Buprenorphine/Naloxone
Bruce RD, Moody DE, Fang WB, Chodkowski D, Andrews L, Friedland GH. Tipranavir/Ritonavir Induction of Buprenorphine Glucuronide Metabolism in HIV-Negative Subjects Chronically Receiving Buprenorphine/Naloxone. The American Journal Of Drug And Alcohol Abuse 2011, 37: 224-228. PMID: 21438849, DOI: 10.3109/00952990.2011.568081.Peer-Reviewed Original ResearchConceptsTPV/rSteady-state pharmacokinetic evaluationGlucuronide metabolitesBUP/naloxoneHIV-negative subjectsHIV-seronegative subjectsBuprenorphine/naloxoneSteady-state pharmacokineticsCytochrome P450 3A4Ritonavir effectsPharmacodynamic consequencesPharmacokinetic evaluationBuprenorphineNorBUPCombined inhibitionNaloxoneCurve AUCP450 3A4AUCSignificant increasePharmacokineticsTipranavirPrevious reportsSubjectsMetabolites
2010
Pharmacokinetic Interactions Between Buprenorphine/Naloxone and Once-Daily Lopinavir/Ritonavir
Bruce RD, Altice FL, Moody DE, Morse GD, Andrews L, Lin SN, Fang WB, Ma Q, Friedland GH. Pharmacokinetic Interactions Between Buprenorphine/Naloxone and Once-Daily Lopinavir/Ritonavir. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2010, 54: 511-514. PMID: 20672450, PMCID: PMC4841260, DOI: 10.1097/qai.0b013e3181d3cad3.Peer-Reviewed Original ResearchConceptsLPV/rBuprenorphine/naloxoneHIV-seronegative subjectsLopinavir/ritonavirOpioid withdrawalPharmacokinetic interactionsDaily lopinavir/ritonavirDaily LPV/rSteady-state pharmacokinetic evaluationBuprenorphine pharmacokineticsR administrationDosage modificationNaloxone concentrationsHistorical controlsPharmacodynamic responseAUC0-24hBaseline valuesPharmacokinetic evaluationNaloxonePharmacokinetic studySignificant differencesRitonavirNLXCmaxClearance
2009
Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone
Bruce RD, Altice FL, Moody DE, Lin SN, Fang WB, Sabo JP, Wruck JM, Piliero PJ, Conner C, Andrews L, Friedland GH. Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone. Drug And Alcohol Dependence 2009, 105: 234-239. PMID: 19726139, PMCID: PMC2779257, DOI: 10.1016/j.drugalcdep.2009.07.007.Peer-Reviewed Original ResearchConceptsTPV/rBuprenorphine/naloxonePharmacokinetic interactionsBuprenorphine/naloxone therapySteady-state pharmacokinetic evaluationOpioid replacement therapyHIV-negative subjectsHIV-seronegative subjectsOpioid withdrawal symptomsHistorical control subjectsTipranavir/ritonavirConcentration-time profilesRTV levelsAntiretroviral medicationsDosage modificationNaloxone therapyTreatment medicationsOpioid dependenceReplacement therapyWithdrawal symptomsControl subjectsPharmacokinetic effectsHIV therapyPharmacokinetic evaluationNLX
1999
Needle-exchange attendance and health care utilization promote entry into detoxification
Strathdee S, Celentano D, Shah N, Lyles C, Stambolis V, Macalino G, Nelson K, Vlahov D. Needle-exchange attendance and health care utilization promote entry into detoxification. Journal Of Urban Health 1999, 76: 448-460. PMID: 10609594, PMCID: PMC3456698, DOI: 10.1007/bf02351502.Peer-Reviewed Original ResearchConceptsUninfected injection drug usersInjection drug usersNeedle exchange programsNeedle exchange attendanceDrug abuse treatmentHospital admissionDrug usersHuman immunodeficiency virus testAbuse treatmentImportant public health goalHIV-seronegative subjectsHealth care utilizationOutpatient medical careHealth care providersRecent drug usePublic health goalsIndependent predictorsCare utilizationHIV serostatusDetoxification admissionsCare providersVirus testHIVNeedle exchangeDrug use
1996
Human Immunodeficiency Virus Infection and Infective Endocarditis among Injecting Drug Users
Manoff S, Vlahov D, Herskowitz A, Solomon L, Munoz A, Cohn S, Willoughby S, Nelson K. Human Immunodeficiency Virus Infection and Infective Endocarditis among Injecting Drug Users. Epidemiology 1996, 7: 566-570. PMID: 8899380, DOI: 10.1097/00001648-199611000-00002.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virus (HIV) infectionHIV-seropositive subjectsImmunodeficiency virus infectionInfective endocarditisDrug usersCD4 cellsOdds ratioVirus infectionHistory of endocarditisRisk of endocarditisHIV-seronegative subjectsInjection drug useInjecting Drug UsersCase-control studyConditional logistic regressionRace/ethnicitySubsequent endocarditisOngoing cohortHIV infectionSerious complicationsHIV serostatusEnrollment dateLast visitCohort enrollmentEndocarditis cases
1995
Instability of Delayed-type Hypersensitivity Skin Test Anergy in Human Immunodeficiency Virus Infection
Caiaffa W, Graham N, Galai N, Rizzo R, Nelson K, Vlahov D. Instability of Delayed-type Hypersensitivity Skin Test Anergy in Human Immunodeficiency Virus Infection. JAMA Internal Medicine 1995, 155: 2111-2117. PMID: 7575072, DOI: 10.1001/archinte.1995.00430190107015.Peer-Reviewed Original ResearchConceptsHIV-seropositive subjectsHIV-seronegative subjectsCD4 cell countSkin test resultsDrug usersCell countDTH anergyDTH positivityDelayed-type hypersensitivity (DTH) skin testDelayed-type hypersensitivity anergyHuman immunodeficiency virus (HIV) infectionDTH skin testingSkin test anergyImmunodeficiency virus infectionCommunity-based cohortHuman immunodeficiency virusHypersensitivity skin testsCandida albicans antigenAnergy testingSerial skinCD4 cellsHIV statusSingle testSkin testingImmunodeficiency virus
1994
Drug smoking, Pneumocystis carinii pneumonia, and immunosuppression increase risk of bacterial pneumonia in human immunodeficiency virus-seropositive injection drug users.
Caiaffa W, Vlahov D, Graham N, Astemborski J, Solomon L, Nelson K, Muñoz A. Drug smoking, Pneumocystis carinii pneumonia, and immunosuppression increase risk of bacterial pneumonia in human immunodeficiency virus-seropositive injection drug users. American Journal Of Respiratory And Critical Care Medicine 1994, 150: 1493-1498. PMID: 7952605, DOI: 10.1164/ajrccm.150.6.7952605.Peer-Reviewed Original ResearchMeSH KeywordsAdultAIDS-Related Opportunistic InfectionsCocaineCohort StudiesCrack CocaineFemaleHIV SeronegativityHIV SeropositivityHIV-1HumansImmunocompromised HostIncidenceMaleMarijuana SmokingOdds RatioPneumoniaPneumonia, PneumocystisRisk FactorsSmokingSubstance Abuse, IntravenousSubstance-Related DisordersConceptsInjection drug usersPneumocystis carinii pneumoniaHIV-seropositive injection drug usersBacterial pneumoniaOdds ratioCarinii pneumoniaCigarette smokingFirst episodeDrug usersIllicit drugsSeropositive injection drug usersCD4 lymphocyte countHIV-seronegative subjectsMedical record reviewHuman immunodeficiency virusCells/Conditional logistic regressionSeronegative subjectsCohort studyLymphocyte countRecord reviewImmunodeficiency virusControl subjectsRisk factorsUnivariate analysisPreparations for AIDS vaccine trials. Incident human immunodeficiency virus (HIV) infections in a cohort of injection drug users in Baltimore, Maryland.
Nelson K, Vlahov D, Galai N, Astemborski J, Solomon L. Preparations for AIDS vaccine trials. Incident human immunodeficiency virus (HIV) infections in a cohort of injection drug users in Baltimore, Maryland. AIDS Research And Human Retroviruses 1994, 10 Suppl 2: s201-5. PMID: 7865301.Peer-Reviewed Original ResearchConceptsInjection drug usersHIV incidenceIncident human immunodeficiency virus (HIV) infectionsDrug usersHIV vaccine trial participationHuman immunodeficiency virus (HIV) infectionRisk behaviorsCohort of IDUsHuman immunodeficiency virus (HIV) vaccinesHIV-seronegative subjectsHigh HIV incidenceImmunodeficiency virus infectionAIDS vaccine trialsVaccine trial participationImmunodeficiency virus vaccinesHigh-risk behaviorsHIV seroconversionAnnual incidenceHIV vaccineNeedle sharingTrial participationVaccine trialsVirus vaccineVirus infectionStudy subjects
1992
Association of Mycoplasma and Human Immunodeficiency Virus Infection: Detection of Amplified Mycoplasma fermentans DNA in Blood
Hawkins R, Rickman L, Vermund S, Carl M. Association of Mycoplasma and Human Immunodeficiency Virus Infection: Detection of Amplified Mycoplasma fermentans DNA in Blood. The Journal Of Infectious Diseases 1992, 165: 581-585. PMID: 1538164, DOI: 10.1093/infdis/165.3.581.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virus (HIV) infectionM. fermentans infectionImmunodeficiency virus infectionVirus infectionHIV clinical stageMycoplasma fermentans infectionHIV-seronegative subjectsHIV-seropositive patientsCross-sectional studyHistory of syphilisAssociation of MycoplasmaHIV infectionOpportunistic infectionsClinical stageLower riskNonsignificant trendPolymerase chain reaction methodologyInfectionPatientsBloodM. fermentansAssociationCopathogensHIVSyphilis
1989
A Prospective Study of the Risk of Tuberculosis among Intravenous Drug Users with Human Immunodeficiency Virus Infection
Selwyn P, Hartel D, Lewis V, Schoenbaum E, Vermund S, Klein R, Walker A, Friedland G. A Prospective Study of the Risk of Tuberculosis among Intravenous Drug Users with Human Immunodeficiency Virus Infection. New England Journal Of Medicine 1989, 320: 545-550. PMID: 2915665, DOI: 10.1056/nejm198903023200901.Peer-Reviewed Original ResearchConceptsHIV-seropositive subjectsIntravenous drug usersPositive PPD testHuman immunodeficiency virus (HIV) infectionImmunodeficiency virus infectionActive tuberculosisPPD testDrug usersSeronegative subjectsSeropositive subjectsTuberculous infectionSkin testingVirus infectionHIV-seronegative intravenous drug usersHIV-seronegative subjectsLatent tuberculous infectionRisk of tuberculosisTuberculin skin testingCases of tuberculosisMethadone maintenance programHIV antibodiesHIV-seropositiveHIV infectionProspective studyProtein derivative (PPD) tuberculin
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply